The spectrum of nonalcoholic fatty liver disease

Peter Ghali, Jayant A. Talwalkar

Research output: Contribution to journalArticle

Abstract

NASH is a highly prevalent disorder in Western society and will likely become more prominent as the epidemic of obesity continues. The cause of NASH is uncertain, but an association with obesity, hypertension, hyperlipidemia, diabetes, and female gender exists. Initial presentation may be with asymptomatic elevation of liver enzymes or incidental radiologic evidence of steatosis. Some individuals presenting with cirrhosis may in fact have had longstanding NASH. This population likely explains a large proportion of individuals diagnosed with cryptogenic cirrhosis. Often, a liver biopsy is required to establish the diagnosis and obtain prognostic information. While no specific therapy currently exists for this condition, there are several promising agents under investigation. However, some of the limitations for studying this disease include its slowly progressive nature, the absence of a reliable, easily obtained gold standard in measuring disease progression, and the absence of large controlled trials to date. Follow-up is required for individuals with NASH, as it may progress to a fibrotic or cirrhotic stage. In this case, consideration should be given to referral for liver transplantation, but this may depend on the patient being an acceptable candidate. Specific risks in this population include morbid obesity, undetected cardiac disease, undetected vascular disease, and severe complications of diabetes and hypertension. Because NASH can recur, risk factors for the disease, such as diabetes and hypertension, should be aggressively managed both before and after liver transplantation.

Original languageEnglish (US)
Pages (from-to)585-593
Number of pages9
JournalJournal of Clinical Outcomes Management
Volume12
Issue number11
StatePublished - Nov 2005

Fingerprint

Hypertension
Liver Transplantation
Obesity
Morbid Obesity
Liver
Diabetes Complications
Hyperlipidemias
Vascular Diseases
Population
Disease Progression
Heart Diseases
Fibrosis
Referral and Consultation
Biopsy
Enzymes
Non-alcoholic Fatty Liver Disease
Fatty liver
Therapeutics
Diabetes
Transplantation

ASJC Scopus subject areas

  • Strategy and Management
  • Medicine(all)

Cite this

Ghali, P., & Talwalkar, J. A. (2005). The spectrum of nonalcoholic fatty liver disease. Journal of Clinical Outcomes Management, 12(11), 585-593.

The spectrum of nonalcoholic fatty liver disease. / Ghali, Peter; Talwalkar, Jayant A.

In: Journal of Clinical Outcomes Management, Vol. 12, No. 11, 11.2005, p. 585-593.

Research output: Contribution to journalArticle

Ghali, P & Talwalkar, JA 2005, 'The spectrum of nonalcoholic fatty liver disease', Journal of Clinical Outcomes Management, vol. 12, no. 11, pp. 585-593.
Ghali, Peter ; Talwalkar, Jayant A. / The spectrum of nonalcoholic fatty liver disease. In: Journal of Clinical Outcomes Management. 2005 ; Vol. 12, No. 11. pp. 585-593.
@article{0851943a2ce942febe732b643c6070bc,
title = "The spectrum of nonalcoholic fatty liver disease",
abstract = "NASH is a highly prevalent disorder in Western society and will likely become more prominent as the epidemic of obesity continues. The cause of NASH is uncertain, but an association with obesity, hypertension, hyperlipidemia, diabetes, and female gender exists. Initial presentation may be with asymptomatic elevation of liver enzymes or incidental radiologic evidence of steatosis. Some individuals presenting with cirrhosis may in fact have had longstanding NASH. This population likely explains a large proportion of individuals diagnosed with cryptogenic cirrhosis. Often, a liver biopsy is required to establish the diagnosis and obtain prognostic information. While no specific therapy currently exists for this condition, there are several promising agents under investigation. However, some of the limitations for studying this disease include its slowly progressive nature, the absence of a reliable, easily obtained gold standard in measuring disease progression, and the absence of large controlled trials to date. Follow-up is required for individuals with NASH, as it may progress to a fibrotic or cirrhotic stage. In this case, consideration should be given to referral for liver transplantation, but this may depend on the patient being an acceptable candidate. Specific risks in this population include morbid obesity, undetected cardiac disease, undetected vascular disease, and severe complications of diabetes and hypertension. Because NASH can recur, risk factors for the disease, such as diabetes and hypertension, should be aggressively managed both before and after liver transplantation.",
author = "Peter Ghali and Talwalkar, {Jayant A.}",
year = "2005",
month = "11",
language = "English (US)",
volume = "12",
pages = "585--593",
journal = "Journal of Clinical Outcomes Management",
issn = "1079-6533",
publisher = "Turner White Communications Inc.",
number = "11",

}

TY - JOUR

T1 - The spectrum of nonalcoholic fatty liver disease

AU - Ghali, Peter

AU - Talwalkar, Jayant A.

PY - 2005/11

Y1 - 2005/11

N2 - NASH is a highly prevalent disorder in Western society and will likely become more prominent as the epidemic of obesity continues. The cause of NASH is uncertain, but an association with obesity, hypertension, hyperlipidemia, diabetes, and female gender exists. Initial presentation may be with asymptomatic elevation of liver enzymes or incidental radiologic evidence of steatosis. Some individuals presenting with cirrhosis may in fact have had longstanding NASH. This population likely explains a large proportion of individuals diagnosed with cryptogenic cirrhosis. Often, a liver biopsy is required to establish the diagnosis and obtain prognostic information. While no specific therapy currently exists for this condition, there are several promising agents under investigation. However, some of the limitations for studying this disease include its slowly progressive nature, the absence of a reliable, easily obtained gold standard in measuring disease progression, and the absence of large controlled trials to date. Follow-up is required for individuals with NASH, as it may progress to a fibrotic or cirrhotic stage. In this case, consideration should be given to referral for liver transplantation, but this may depend on the patient being an acceptable candidate. Specific risks in this population include morbid obesity, undetected cardiac disease, undetected vascular disease, and severe complications of diabetes and hypertension. Because NASH can recur, risk factors for the disease, such as diabetes and hypertension, should be aggressively managed both before and after liver transplantation.

AB - NASH is a highly prevalent disorder in Western society and will likely become more prominent as the epidemic of obesity continues. The cause of NASH is uncertain, but an association with obesity, hypertension, hyperlipidemia, diabetes, and female gender exists. Initial presentation may be with asymptomatic elevation of liver enzymes or incidental radiologic evidence of steatosis. Some individuals presenting with cirrhosis may in fact have had longstanding NASH. This population likely explains a large proportion of individuals diagnosed with cryptogenic cirrhosis. Often, a liver biopsy is required to establish the diagnosis and obtain prognostic information. While no specific therapy currently exists for this condition, there are several promising agents under investigation. However, some of the limitations for studying this disease include its slowly progressive nature, the absence of a reliable, easily obtained gold standard in measuring disease progression, and the absence of large controlled trials to date. Follow-up is required for individuals with NASH, as it may progress to a fibrotic or cirrhotic stage. In this case, consideration should be given to referral for liver transplantation, but this may depend on the patient being an acceptable candidate. Specific risks in this population include morbid obesity, undetected cardiac disease, undetected vascular disease, and severe complications of diabetes and hypertension. Because NASH can recur, risk factors for the disease, such as diabetes and hypertension, should be aggressively managed both before and after liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=29244457818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29244457818&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:29244457818

VL - 12

SP - 585

EP - 593

JO - Journal of Clinical Outcomes Management

JF - Journal of Clinical Outcomes Management

SN - 1079-6533

IS - 11

ER -